Secretome Therapeutics, a clinical-stage biotechnology company developing novel therapies derived from neonatal cardiac progenitor cells, today announced that the company’s management team will participate in the following upcoming investor conferences through 2026.

Cantor Global Healthcare Conference

September 9–11, 2026

Oppenheimer’s Private Life Sciences Company Showcase

September 29, 2026

Stifel 2026 Virtual Cardiometabolic Forum

September 30, 2026

Leerink Partners Biopharma Private Company Connect

October 20–21, 2026

38th Annual Piper Sandler Healthcare Conference

December 1–3, 2026

About Secretome Therapeutics

Secretome Therapeutics is a clinical-stage biotechnology company based in Plano, Texas, developing novel therapies derived from neonatal cardiac progenitor cells. The Company’s lead product candidate, STM-01, is a cellular therapy designed to modulate inflammatory and fibrotic pathways and support myocardial function in Duchenne muscular dystrophy, dilated cardiomyopathy, and heart failure with preserved ejection fraction. Secretome is also advancing STM-21, a secretome-based therapeutic currently in preclinical development, and other novel nCPC-based products.

Media gallery

About The Author
Business Wire